



Supporting Information

for

[3 + 2] Cycloaddition of thioformylium methylide with various arylidene-azolones in the synthesis of 7-thia-3-azaspiro[4.4]nonan-4-ones

Daniil I. Rudik, Irina V. Tiushina, Anatoly I. Sokolov, Alexander Yu. Smirnov, Alexander R. Romanenko, Alexander A. Korlyukov, Andrey A. Mikhaylov and Mikhail S. Baranov

Beilstein J. Org. Chem. **2025**, *21*, 1791–1798. doi:10.3762/bjoc.21.141

Experimental part, X-ray data and copies of NMR spectra

Contents

1. General.....	S2
2. Optimization	S3
2.1. Step 1	S3
2.2. Step 2	S6
3. Synthesis of spiro-products 6–9	S7
4. Derivatization study	S18
4.1. Hydrolysis of compounds 6a , 7a , 8c and 9a	S18
4.2. Oxidation of compounds 7c , 7e and 9e	S19
5. X-ray crystallography	S22
6. References	S24
7. Copies of NMR spectra	S25
8. Copies of mass-spectra	S48

1. General

NMR spectra were recorded on a 700 MHz Bruker Avance III NMR, 800 MHz Bruker Avance III 800 and Bruker Fourier 300 at 303°K. Chemical shifts are reported relative to residue peaks of CDCl₃ (7.27 ppm for ¹H and 77.2 ppm for ¹³C) or DMSO-*d*₆ (2.50 ppm for ¹H and 39.5 ppm for ¹³C). Melting points were measured on a SMP 30 apparatus without correction. High-resolution mass spectra (HRMS) spectra were recorded on AB Sciex TripleTOF® 5600+ System using electrospray ionization (ESI). The measurements were done in a positive ion mode (interface capillary voltage – 5500 V); mass range from *m/z* 50 to *m/z* 3000; external or internal calibration was done with ESI Tuning Mix, Agilent. A syringe injection was used for solutions in methanol +0.1 % formic acid (flow rate 100 µL/min). Nitrogen was applied as a dry gas; interface temperature was set at 200 °C.

Commercially available reagents were used without additional purification. Solvents were distilled before use. E. Merck Kieselgel 60 was used for column chromatography. Thin layer chromatography (TLC) was performed on silica gel 60F₂₅₄ glass-backed plates (MERCK). Visualization was performed using UV light (254 or 312 nm) or staining with ethanol solution of phosphomolybdic acid.

Arylidene-azolones **1–3**, **5**¹ and arylidene-imidazolones **4**^{2,3} was synthesized and described in previous works. (((Chloromethyl)thio)methyl)trimethylsilane was synthesized according to literature.⁴

2. Optimization

2.1. Step 1

The first optimization was carried out on azolone **3e** in order to determine the solvent and fluorine source suitable for the cycloaddition reaction.




Table S1. First optimization.

Nº	Solvent	Promoter	T (°C)	Time (h)	Yield (%)
1	DMF	LiF	25	72	-
2	DMF	LiF	155	72	-
3	MeCN	LiF	25	72	-
4	MeCN	LiF	80	72	-
5	THF	TBAF	25	72	85
6	MeCN	CsF	25	72	97
7	THF	TFA	25	72	-

Cycloaddition procedure variant 1:

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in DMF (3 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and LiF (18 mg, 2 equiv) was added to the solution. The reaction mixture was stirred for 72 h at room temperature. The reaction progress was monitored with TLC. After 72 h aliquot (75 µL) was evaporated, dissolved in CDCl₃ and ¹H NMR spectrum was recorded. The obtained spectrum demonstrated that there is no desired product formed.

Cycloaddition procedure variant 2:

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in DMF (3 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and LiF (18 mg, 2 equiv) was added to the solution. The reaction mixture was stirred for 72 h on oil bath at 155 °C. The reaction progress was monitored with TLC. After 72 h aliquot (75 µL) was evaporated, dissolved in CDCl₃ and ¹H NMR spectrum was recorded. The obtained spectrum demonstrated that there is no desired product formed.

Cycloaddition procedure variant 3:

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in MeCN (3 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and LiF (18 mg, 2 equiv) was added to the solution. The reaction mixture was stirred for 72 h at room temperature. The reaction progress was monitored with TLC. After 72 h aliquot (75 μ L) was evaporated, dissolved in CDCl_3 and ^1H NMR spectrum was recorded. The obtained spectrum demonstrated that there is no desired product formed.

Cycloaddition procedure variant 4:

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in MeCN (3 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and LiF (18 mg, 2 equiv) was added to the solution. The reaction mixture was stirred for 72 h on oil bath at 80 $^\circ\text{C}$. The reaction progress was monitored with TLC. After 72 h aliquot (75 μ L) was evaporated, dissolved in CDCl_3 and ^1H NMR spectrum was recorded. The obtained spectrum demonstrated that there is no desired product formed.

Cycloaddition procedure variant 5 (Method A):

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in THF (2 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and TBAF \cdot 3H $_2$ O (144 mg, 1.3 equiv) was added to the solution. The reaction mixture was stirred at least 24 h. The reaction progress was monitored with TLC. In cases when reaction progress stopped after 24 hours a new portion of (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and TBAF \cdot 3H $_2$ O (144 mg, 1.3 equiv) was added and the reaction mixture was stirred for additional 12–24 h (this step should be repeated if the starting material was still observed at TLC). Once complete, the reaction mixture was diluted with EtOAc (50 mL) and transferred to a separatory funnel. The mixture was washed with saturated KCl solution (3 \times 10 mL). The organic phase was dried over anhydrous Na $_2$ SO $_4$ and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex).

Cycloaddition procedure variant 6 (Method B):

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in MeCN (3 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and CsF (107 mg, 2 equiv) was added to the solution. The reaction mixture was stirred at least 24 h. The reaction progress was monitored with TLC. In cases when reaction progress stopped after 24 hours a new portion of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (107 mg, 2 equiv) was added and the reaction mixture was stirred for additional 12–24 h (this step should be repeated if the

starting material was still observed at TLC). Once complete, the reaction mixture was diluted with EtOAc (50 mL) and transferred to a separatory funnel. The mixture was washed with saturated K_2CO_3 solution (2×15 mL) and then with sat. KCl solution (3×15 mL). The organic phase was dried over anhydrous Na_2SO_4 and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex).

Cycloaddition procedure variant 7:

Arylideneazalone (0.35 mmol, 1 equiv) was dissolved in 1% TFA in THF (3 mL, 0.17 equiv) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) was added to the solution. The reaction mixture was stirred for 72 h at room temperature. The reaction progress was monitored with TLC. After 72 h aliquot (75 μL) was evaporated, dissolved in CDCl_3 and ^1H NMR spectrum was recorded. The obtained spectrum demonstrated that there is no desired product formed.

2.2. Step 2

The second optimization was performed for each series of azolones using the most successful methods A and B. For the second optimization, para-methoxy substituted azolones were also used.




Table S2. Second optimization.

№	Azolone	Method A	Method B
1	1e	72% (Single isomer)	73% (Single isomer)
2	2e	98% (Single isomer)	84% (Single isomer)
3	3e	85% (Single isomer)	97% (Single isomer)
4	4e	99% (Single isomer)	58% (Single isomer)
5	5e	Complex reaction mixture	Complex reaction mixture


3. Synthesis of spiro-products 6–9

Method A

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in THF (2 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and TBAF·3H₂O (144 mg, 1.3 equiv) was added to the solution. The reaction mixture was stirred at least 24 h. The reaction progress was monitored with TLC. In cases when reaction progress stopped after 24 hours a new portion of (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and TBAF·3H₂O (144 mg, 1.3 equiv) was added and the reaction mixture was stirred for additional 12–24 h (this step should be repeated if the starting material was still observed at TLC). Once complete, the reaction mixture was diluted with EtOAc (50 mL) and transferred to a separatory funnel. The mixture was washed with saturated KCl solution (3 × 10 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex).

Method B

Arylideneazolone (0.35 mmol, 1 equiv) was dissolved in MeCN (3 mL) then (((chloromethyl)thio)methyl)trimethylsilane (88 mg, 1.5 equiv) and CsF (107 mg, 2 equiv) was added to the solution. The reaction mixture was stirred at least 24 h. The reaction progress was monitored with TLC. In cases when reaction progress stopped after 24 hours a new portion of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (107 mg, 2 equiv) was added and the reaction mixture was stirred for additional 12–24 h (this step should be repeated if the starting material was still observed at TLC). Once complete, the reaction mixture was diluted with EtOAc (50 mL) and transferred to a separatory funnel. The mixture was washed with saturated K₂CO₃ solution (2 × 15 mL) and then with sat. KCl solution (3 × 15 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex).



***cis*-3-Methyl-9-phenyl-1,7-dithia-3-azaspiro[4.4]nonane-2,4-dione (6a)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 70 mg (71%). White solid. M.p. 81-85 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.29 - 7.32 (m, 3 H), 7.24 - 7.26 (m, 2 H), 4.05 (dd, *J*=12.0, 7.4 Hz, 1 H), 3.94 (d, *J*=11.2 Hz, 1 H), 3.36 (t, *J*=11.5 Hz, 1 H), 3.26 - 3.30 (m, 2 H), 2.85 (s, 3 H).

¹³C NMR (201 MHz, CDCl₃) δ ppm 174.2, 169.6, 133.7, 128.7, 128.6, 128.3, 72.0, 57.3, 42.2, 32.5, 27.6.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₃H₁₄NO₂S₂⁺: 280.0460, found: 280.0461.



***cis*-9-(4-Bromophenyl)-3-methyl-1,7-dithia-3-azaspiro[4.4]nonane-2,4-dione (6b)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 68 mg (54%). White solid. M.p. 87-89 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.41 - 7.46 (m, 2 H), 7.11 - 7.15 (m, 2 H), 4.01 (dd, *J*=10.7, 8.5 Hz, 1 H), 3.92 (d, *J*=11.3 Hz, 1 H), 3.24 - 3.31 (m, 3 H), 2.90 (s, 3 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 174.0, 169.3, 132.8, 131.6, 130.2, 122.9, 71.7, 56.5, 42.5, 32.6, 27.8.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₃H₁₃BrNO₂S₂⁺: 357.9566, found: 357.9566.



***cis*-3-Methyl-9-(4-nitrophenyl)-1,7-dithia-3-azaspiro[4.4]nonane-2,4-dione (6c)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 42 mg (37%). White solid. M.p. 203-204 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 8.18 (m, *J*=8.7 Hz, 2 H), 7.46 (m, *J*=8.6 Hz, 2 H), 4.17 (dd, *J*=11.4, 7.7 Hz, 1 H), 3.95 (d, *J*=11.3 Hz, 1 H), 3.29 - 3.38 (m, 3 H), 2.91 (s, 3 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 173.7, 168.8, 148.1, 141.3, 129.7, 123.5, 71.6, 56.4, 42.9, 32.6, 28.0.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₃H₁₃N₂O₄S₂⁺: 325.0311, found: 325.0309.



***cis*-9-(4-Methoxyphenyl)-3-methyl-1,7-dithia-3-azaspiro[4.4]nonane-2,4-dione (6e)**


The compound was synthesized according to **Method B**. Two additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 79 mg (73%). slightly yellow solid. M.p. 144-146 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.18 (m, *J*=8.4 Hz, 2 H), 6.82 (m, *J*=8.5 Hz, 2 H), 4.01 (dd, *J*=11.9, 7.4 Hz, 1 H), 3.92 (d, *J*=11.3 Hz, 1 H), 3.79 (s, 3 H), 3.30 (t, *J*=11.4 Hz, 1 H), 3.22 - 3.27 (m, 2 H), 2.87 (s, 3 H).

¹³C NMR (201 MHz, CDCl₃) δ ppm 174.3, 169.7, 159.7, 129.7, 125.5, 113.7, 72.1, 56.7, 55.2, 42.1, 32.7, 27.7.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₄H₁₆NO₃S₂⁺: 310.0566, found: 310.0568.



7a

***trans*-1-Methyl-3,9-diphenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7a)**


The compound was synthesized according to **Method A**. Two additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) were added.

Yield: 74 mg (60%). Beige solid. M.p. 210-212 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.35 - 7.39 (m, 3 H), 7.30 - 7.34 (m, 3 H), 7.19 (d, *J*=7.3 Hz, 2 H), 6.58 (d, *J*=6.4 Hz, 2 H), 3.97 (t, *J*=11.7 Hz, 1 H), 3.89 (dd, *J*=12.6, 5.8 Hz, 1 H), 3.54 (s, 3 H), 3.52 (d, *J*=12.5 Hz, 1 H), 3.30 (d, *J*=12.6 Hz, 1 H), 3.10 (dd, *J*=11.0, 5.6 Hz, 1 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 181.7, 173.3, 134.1, 132.6, 129.0, 128.9, 128.9, 128.6, 128.0, 127.9, 77.0, 55.4, 33.5, 32.0, 30.0..

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₉H₁₉N₂OS₂⁺: 355.0933, found: 355.0932.



7b

***trans*-9-(4-Bromophenyl)-1-methyl-3-phenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7b)**


The compound was synthesized according to **Method A**. Two additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) were added.

Yield: 105 mg (69%). White solid. M.p. 189-190 °C decomp.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.50 (d, *J*=7.0 Hz, 2 H), 7.37 (d, *J*=4.1 Hz, 3 H), 7.06 (d, *J*=7.3 Hz, 2 H), 6.61 (br. s., 2 H), 3.90 (t, *J*=11.7 Hz, 1 H), 3.83 - 3.87 (m, 1 H), 3.49 - 3.55 (m, 4 H), 3.28 (d, *J*=12.6 Hz, 1 H), 3.08 (dd, *J*=10.8, 5.5 Hz, 1 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 181.7, 173.2, 133.2, 132.5, 132.1, 129.6, 129.2, 129.0, 127.9, 122.8, 76.9, 54.9, 33.5, 32.1, 30.0.

HRMS (ESI) m/z $[M+H]^+$ calcd for $C_{19}H_{18}BrN_2OS_2^+$: 433.0038, found: 433.0037.



***trans*-1-Methyl-9-(4-nitrophenyl)-3-phenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7c)**


The compound was synthesized according to **Method A**. Two additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) were added.

Yield: 87 mg (62%). White solid. M.p. >250 °C decomp.

1H NMR (800 MHz, $CDCl_3$) δ ppm 8.22 (m, $J=8.7$ Hz, 2 H), 7.38 (m, $J=8.6$ Hz, 2 H), 7.32 - 7.36 (m, 3 H), 6.61 (d, $J=7.1$ Hz, 2 H), 3.95 - 4.01 (m, 2 H), 3.56 (s, 3 H), 3.56 (d, $J=12.6$ Hz, 2 H), 3.33 (d, $J=12.6$ Hz, 1 H), 3.14 (dd, $J=9.4, 4.0$ Hz, 1 H)

^{13}C NMR (201 MHz, $CDCl_3$) δ ppm 181.5, 172.9, 148.0, 141.9, 132.2, 129.3, 129.1, 129.0, 127.6, 123.9, 55.0, 34.0, 32.3, 30.0.

HRMS (ESI) m/z $[M+H]^+$ calcd for $C_{19}H_{18}N_3O_3S_2^+$: 400.0784, found: 400.0782.



***trans*-9-(4-(Dimethylamino)phenyl)-1-methyl-3-phenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7d)**


The compound was synthesized according to **Method A**. Five additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) were added.

Yield: 88 mg (63%). White solid. M.p. 202-203 °C.

^1H NMR (800 MHz, CDCl_3) δ ppm 7.31 - 7.35 (m, 3 H), 7.04 (d, $J=8.3$ Hz, 2 H), 6.67 (d, $J=8.2$ Hz, 4 H), 3.91 (t, $J=11.7$ Hz, 1 H), 3.81 (dd, $J=12.5$, 5.8 Hz, 1 H), 3.51 (s, 3 H), 3.48 (d, $J=12.5$ Hz, 1 H), 3.27 (d, $J=12.5$ Hz, 1 H), 3.05 (dd, $J=11.0$, 5.8 Hz, 1 H), 2.95 (s, 6 H)

^{13}C NMR (201 MHz, CDCl_3) δ ppm 181.8, 173.7, 150.8, 132.9, 129.0, 128.8, 128.6, 128.3, 120.9, 112.6, 77.1, 55.0, 40.5, 33.2, 32.2, 30.0.

HRMS (ESI) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{24}\text{N}_3\text{OS}_2^+$: 398.1355, found: 398.1353.



***trans*-9-(4-Methoxyphenyl)-1-methyl-3-phenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7e)**


The compound was synthesized according to **Method A**. One additional portion of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) was added.

Yield: 132 mg (98%). Beige solid. M.p. 190-191 °C decomp.

^1H NMR (800 MHz, CDCl_3) δ ppm 7.34 (d, $J=3.4$ Hz, 3 H), 7.11 (m, $J=8.4$ Hz, 2 H), 6.88 (m, $J=8.4$ Hz, 2 H), 6.66 (d, $J=3.4$ Hz, 2 H), 3.92 (t, $J=11.7$ Hz, 1 H), 3.85 (dd, $J=12.4$, 5.7 Hz, 1 H), 3.81 (s, 3 H), 3.52 (s, 3 H), 3.49 (d, $J=12.5$ Hz, 1 H), 3.28 (d, $J=12.5$ Hz, 1 H), 3.07 (dd, $J=11.0$, 5.8 Hz, 1 H)

^{13}C NMR (201 MHz, CDCl_3) δ ppm 181.7, 173.4, 159.9, 132.7, 129.1, 129.0, 128.9, 128.1, 125.8, 114.3, 77.0, 55.4, 54.7, 33.3, 32.2, 30.0.

HRMS (ESI) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{21}\text{N}_2\text{O}_2\text{S}_2^+$: 385.1039, found: 385.1040.



***trans*-1-Methyl-3-phenyl-9-(thiophen-2-yl)-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7f)**


The compound was synthesized according to **Method A**. Five additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) were added.

Yield: 22 mg (17%). Beige solid. M.p. 145-146 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.35 - 7.38 (m, 3 H), 7.31 (d, *J*=5.0 Hz, 1 H), 7.04 (t, *J*=4.3 Hz, 1 H), 6.95 (d, *J*=3.1 Hz, 1 H), 6.75 (d, *J*=3.1 Hz, 2 H), 4.13 (dd, *J*=12.2, 6.0 Hz, 1 H), 3.94 (t, *J*=11.6 Hz, 1 H), 3.51 (s, 3 H), 3.47 (d, *J*=12.3 Hz, 1 H), 3.33 (d, *J*=12.3 Hz, 1 H), 3.23 (dd, *J*=10.9, 6.1 Hz, 1 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 182.3, 172.9, 135.9, 132.7, 129.1, 129.0, 128.1, 127.3, 125.9, 125.5, 76.6, 49.8, 32.8, 32.6, 29.7.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₇H₁₇N₂OS₃⁺: 361.0498, found: 361.0501.



***trans*-1-Methyl-3-phenyl-9-(pyridin-4-yl)-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one (7g)**


The compound was synthesized according to **Method A**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) were added.

Yield: 91 mg (73%). White solid. M.p. 187-188 °C decomp.

¹H NMR (800 MHz, CDCl₃) δ ppm 8.61 (d, *J*=5.7 Hz, 2 H), 7.33 - 7.37 (m, 3 H), 7.11 (d, *J*=5.8 Hz, 2 H), 6.59 (d, *J*=5.6 Hz, 2 H), 3.95 (t, *J*=11.8 Hz, 1 H), 3.86 (dd, *J*=12.4, 5.8 Hz, 1 H), 3.52 - 3.55 (m, 4 H), 3.31 (d, *J*=12.6 Hz, 1 H), 3.11 (dd, *J*=11.1, 5.8 Hz, 1 H)

^{13}C NMR (201 MHz, CDCl_3) δ ppm 181.7, 172.9, 150.4, 143.5, 132.3, 129.3, 129.1, 127.8, 122.9, 76.7, 54.4, 33.9, 31.7, 30.0.

HRMS (ESI) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{18}\text{N}_3\text{OS}_2^+$: 356.0886, found: 356.0888.



***cis*-3-Methyl-9-phenyl-2-thioxo-1,7-dithia-3-azaspiro[4.4]nonan-4-one (8a)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 66 mg (64%). White solid. M.p. 104-105 °C.

^1H NMR (800 MHz, CDCl_3) δ ppm 7.28 - 7.32 (m, 3 H), 7.24 - 7.26 (m, 2 H), 4.03 (dd, $J=11.8$, 7.4 Hz, 1 H), 3.90 (d, $J=11.3$ Hz, 1 H), 3.37 (t, $J=11.4$ Hz, 1 H), 3.27 - 3.32 (m, 2 H), 3.11 (s, 3 H)

^{13}C NMR (201 MHz, CDCl_3) δ ppm 198.5, 175.5, 133.5, 128.8, 128.4, 73.0, 57.8, 41.4, 32.7, 31.0.

HRMS (ESI) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{14}\text{NOS}_3^+$: 296.0232, found: 296.0237.



***cis*-9-(4-Bromophenyl)-3-methyl-2-thioxo-1,7-dithia-3-azaspiro[4.4]nonan-4-one (8b)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 119 mg (91%). Beige solid. M.p. 110-112 °C.

^1H NMR (800 MHz, CDCl_3) δ ppm 7.42 (m, $J=8.4$ Hz, 2 H), 7.14 (m, $J=8.4$ Hz, 2 H), 3.97 - 4.02 (m, 1 H), 3.88 (d, $J=11.3$ Hz, 1 H), 3.26 - 3.30 (m, 3 H), 3.16 (s, 3 H)

^{13}C NMR (201 MHz, CDCl_3) δ ppm 198.0, 175.4, 132.7, 131.6, 130.1, 123.0, 72.6, 56.9, 41.8, 32.8, 31.2.

HRMS (ESI) m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{13}\text{BrNOS}_3^+$: 373.9337, found: 373.9337.



***cis*-3-Methyl-9-(4-nitrophenyl)-2-thioxo-1,7-dithia-3-azaspiro[4.4]nonan-4-one (8c)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 27 mg (23%). Slightly yellow solid. M.p. 176-177 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 8.16 (m, *J*=8.6 Hz, 2 H), 7.46 (m, *J*=8.6 Hz, 2 H), 4.15 (dd, *J*=11.2, 8.0 Hz, 1 H), 3.92 (d, *J*=11.4 Hz, 1 H), 3.34 - 3.38 (m, 2 H), 3.32 (d, *J*=11.4 Hz, 1 H), 3.16 (s, 3 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 197.3, 175.1, 148.1, 141.1, 129.6, 123.5, 72.5, 56.8, 42.1, 32.7, 31.3.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₃H₁₃N₂O₃S₃⁺: 341.0083, found: 341.0082.



***cis*-9-(4-Methoxyphenyl)-3-methyl-2-thioxo-1,7-dithia-3-azaspiro[4.4]nonan-4-one (8e)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 110 mg (97%). White solid. M.p. 96-98 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.17 (m, *J*=8.6 Hz, 2 H), 6.80 (m, *J*=8.7 Hz, 2 H), 4.00 (dd, *J*=11.7, 7.5 Hz, 1 H), 3.87 (d, *J*=11.3 Hz, 1 H), 3.78 (s, 3 H), 3.30 (t, *J*=11.4 Hz, 1 H), 3.24 - 3.28 (m, 2 H), 3.13 (s, 3 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 198.7, 175.6, 159.8, 129.5, 125.3, 113.7, 73.1, 57.2, 55.2, 41.3, 32.9, 31.1.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₄H₁₆NO₂S₃⁺: 326.0338, found: 326.0343.



***cis*-3-Methyl-9-(thiophen-2-yl)-2-thioxo-1,7-dithia-3-azaspiro[4.4]nonan-4-one (8f)**


The compound was synthesized according to **Method B**. Three additional portions of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and CsF (2 equiv) were added.

Yield: 47 mg (45%). White solid. M.p. 93-94 °C.

¹H NMR (800 MHz, CDCl₃) δ ppm 7.22 - 7.25 (m, 1 H), 6.92 - 6.95 (m, 2 H), 4.34 (dd, *J*=11.8, 7.2 Hz, 1 H), 3.86 (d, *J*=11.3 Hz, 1 H), 3.40 (dd, *J*=11.0, 7.3 Hz, 1 H), 3.29 (d, *J*=11.3 Hz, 1 H), 3.21 - 3.25 (m, 4 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 198.7, 175.4, 136.2, 126.8, 126.7, 125.8, 72.6, 53.5, 41.2, 34.5, 31.3.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₁H₁₂NOS₄⁺: 301.9796, found: 301.9799.



***cis*-2,3-Dimethyl-9-phenyl-7-thia-1,3-diazaspiro[4.4]non-1-en-4-one (9a)**


Yield: 57 mg (63%). White solid. M.p. 112-113 °C.

The compound was synthesized according to **Method A**. One additional portion of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) was added.

¹H NMR (800 MHz, CDCl₃) δ ppm 3.70 - 3.74 (m, 1 H), 3.66 (dd, *J*=12.3, 10.1 Hz, 1 H), 3.50 (d, *J*=11.0 Hz, 1 H), 3.24 (dd, *J*=10.0, 6.5 Hz, 1 H), 2.90 (d, *J*=10.9 Hz, 1 H), 2.72 (s, 3 H), 2.00 (s, 3 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 181.5, 160.8, 134.9, 128.6, 127.6, 127.7, 80.7, 58.5, 38.6, 34.8, 26.4, 15.1.

HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₄H₁₇N₂OS⁺: 261.1056, found: 261.1057.



***cis*-9-(4-Methoxyphenyl)-2,3-dimethyl-7-thia-1,3-diazaspiro[4.4]non-1-en-4-one (9e)**

The compound was synthesized according to **Method A**. One additional portion of (((chloromethyl)thio)methyl)trimethylsilane (1.5 equiv) and TBAF (1.3 equiv) was added.

Yield: 100 mg (99%). Slightly yellow solid. M.p. 135-137 °C.


¹H NMR (800 MHz, CDCl₃) δ ppm 7.12 (m, *J*=8.8 Hz, 2 H), 6.75 (m, *J*=8.8 Hz, 2 H), 3.77 (s, 3 H), 3.68 (dd, *J*=12.4, 6.7 Hz, 1 H), 3.60 (dd, *J*=12.3, 10.3 Hz, 1 H), 3.48 (d, *J*=11.0 Hz, 1 H), 3.20 (dd, *J*=10.2, 6.7 Hz, 1 H), 2.88 (d, *J*=11.0 Hz, 1 H), 2.74 (s, 3 H), 2.03 (s, 3 H)

¹³C NMR (201 MHz, CDCl₃) δ ppm 181.6, 160.8, 159.0, 129.6, 126.9, 113.0, 80.6, 57.8, 55.1, 38.5, 35.0, 26.4, 15.1.


HRMS (ESI) *m/z* [M+H]⁺ calcd for C₁₅H₁₉N₂O₂S⁺: 291.1162, found: 291.1165.

4. Derivatization study


4.1. Hydrolysis of compounds 6a, 7a, 8c and 9a



Corresponding spiro-compound (0.1 mmol, 1 equiv) was dissolved in MeOH (2 mL) and KOH (20 equiv) was added to the solution. The reaction mixture was refluxed for 4 hours. The reaction progress was monitored with TLC.




Corresponding spiro-compound (0.1 mmol, 1 equiv) was dissolved in MeOH (2 mL) and KOH (20 equiv) was added to the solution. The reaction mixture was stirred at room temperature for 1 minute. The reaction mixture was diluted with EtOAc (20 mL) and transferred to a separatory funnel. The mixture was washed with water, saturated and KCl solution (3×20 mL). The organic phase was dried over anhydrous Na_2SO_4 and concentrated in vacuo. TLC showed a spot, which was no longer detectable after solvent removal under reduced pressure.



Corresponding spiro-compound (0.1 mmol, 1 equiv) was dissolved in MeOH (1 mL) and concentrated HCl (1 mL) was added to the solution. The reaction mixture was refluxed for 4 hours. The reaction progress was monitored with TLC.

4.2. Oxidation of compounds 7c, 7e and 9e




***trans*-9-(4-Methoxyphenyl)-1-methyl-3-phenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one 7-oxide (11e)**

Compound **7e** (0.1 mmol, 1 equiv) was dissolved in MeOH (2 mL) and H₂O₂ 30% (40 equiv, 0.41 mL) was added to the solution. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with CHCl₃ (20 mL) and transferred to a separatory funnel. The mixture was washed with water (1 × 10 mL), saturated and KCl solution (3 × 20 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex, v/v 3:1).

Yield: 32 mg (80%). White solid. M.p. 239-241 °C.

¹H NMR (300 MHz, CDCl₃) δ ppm 7.29 - 7.36 (m, 3 H), 7.12 (m, *J*=8.6 Hz, 2 H), 6.93 (m, *J*=8.6 Hz, 2 H), 6.47 – 6.55 (m, *J*=5.3, 2.5 Hz, 2 H), 4.85 (dd, *J*=14.4, 4.9 Hz, 1 H), 3.83 (s, 3 H), 3.71 (d, *J*=15.5 Hz, 1 H), 3.63 (s, 3 H), 3.56 (t, *J*=13.8 Hz, 1 H), 3.31 - 3.41 (m, 1 H), 3.21 (dd, *J*=15.4, 3.4 Hz, 1 H)

¹³C NMR (75 MHz, CDCl₃) δ ppm 181.7, 173.4, 160.1, 132.4, 129.4, 129.2, 128.9, 127.9, 123.8, 114.5, 76.2, 57.1, 55.4, 52.9, 48.7, 31.1.



***trans*-1-Methyl-9-(4-nitrophenyl)-3-phenyl-2-thioxo-7-thia-1,3-diazaspiro[4.4]nonan-4-one 7-oxide (11c)**


Compound **7c** (0.1 mmol, 1 equiv) was dissolved in MeOH (2 mL) and H₂O₂ 30% (0.41 mL, 40 equiv) was added to the solution. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with CHCl₃ (20 mL) and transferred to a separatory funnel. The mixture was washed with water (1 × 10 mL) and saturated NaCl solution

(3x20 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex, v/v 3:1).

Yield: 30 mg (72%). White solid. M.p. > 250 °C.

¹H NMR (300 MHz, CDCl₃) δ ppm 8.27 (d, *J*=8.7 Hz, 2 H), 7.30 - 7.44 (m, 5 H), 6.43 - 6.54 (m, 2 H), 5.00 (dd, *J*=14.2, 4.8 Hz, 1 H), 3.74 (d, *J*=15.5 Hz, 1 H), 3.55 - 3.70 (m, 4 H), 3.40 - 3.49 (m, 1 H), 3.28 (dd, *J*=15.4, 3.3 Hz, 1 H)

¹³C NMR (75 MHz, CDCl₃) δ ppm 181.5, 172.8, 148.2, 139.8, 132.0, 129.5, 129.4, 129.2, 127.4, 124.1, 76.0, 57.4, 52.6, 48.9, 31.2.



13e

***cis*-9-(4-methoxyphenyl)-2,3-dimethyl-7-thia-1,3-diazaspiro[4.4]non-1-en-4-one 7-oxide (13e)**


Compound 9e (0.1 mmol, 1 equiv) was dissolved in MeOH (2 mL) and H₂O₂ 30% (0.41 mL, 40 equiv) was added to the solution. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with CHCl₃ (20 mL) and transferred to a separatory funnel. The mixture was washed with water (1 × 10 mL) and saturated NaCl solution (3 × 20 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – CHCl₃/MeOH, v/v 25:1).

Yield: 19 mg (63%). White viscous paste.

The compound was isolated as a diastereomeric mixture (4:1). The description of the major isomer is given below.

¹H NMR (300 MHz, CDCl₃) δ ppm 7.09 (d, *J*=8.6 Hz, 2 H), 6.77 (d, *J*=8.7 Hz, 2 H), 4.49 (dd, *J*=13.8, 5.4 Hz, 1 H), 3.78 (s, 3 H), 3.68 (d, *J*=13.8 Hz, 1 H), 3.56 (t, *J*=13.6 Hz, 1 H), 3.27 (dd, *J*=13.4, 5.3 Hz, 1 H), 3.14 (dd, *J*=13.9, 0.8 Hz, 1 H), 2.78 (s, 3 H), 1.95 (s, 3 H)

¹³C NMR (75 MHz, CDCl₃) δ ppm 180.2, 161.4, 159.2, 129.5, 124.8, 113.2, 79.3, 63.4, 56.2, 55.1, 52.7, 26.6, 15.1.



***trans*-9-(4-Methoxyphenyl)-1-methyl-3-phenyl-7-thia-1,3-diazaspiro[4.4]nonane-2,4-dione 7,7-dioxide (12e)**

Compound 7e (0.1 mmol, 1 equiv) was dissolved in MeOH (2 mL) and H₂O₂ 30% (5 equiv, 52 μ L) was added to the solution. The reaction mixture was stirred at room temperature overnight and subsequently concentrated in vacuo. The crude product was purified by flash column chromatography (eluent – EtOAc/Hex, v/v 1:1).

Yield: 22 mg (55%). White solid. M.p. 210-212 °C.

¹H NMR (300 MHz, CDCl₃) δ ppm 7.29 - 7.36 (m, 3 H), 7.11 (m, *J*=8.7 Hz, 2 H), 6.90 (m, *J*=8.6 Hz, 2 H), 6.69 - 6.79 (m, 2 H), 4.05 - 4.23 (m, 2 H), 3.88 (d, *J*=14.9 Hz, 1 H), 3.80 (s, 3 H), 3.35 - 3.49 (m, 2 H), 3.25 (s, 3 H)

¹³C NMR (75 MHz, CDCl₃) δ ppm 171.4, 160.3, 153.9, 130.4, 129.1, 129.0, 128.6, 125.9, 122.6, 114.6, 68.8, 55.4, 53.7, 52.8, 44.9, 25.3.

5. X-ray crystallography

Single crystal X-ray studies of **6e**, **7d**, **8e** and **9e** were carried out in Center for Collective Use of INEOS RAS with Bruker APEX II diffractometer and APEX3 software.⁵ The data collected were then integrated with SAINT. SADABS was used for scaling, empirical absorption corrections and the generation of data files for structure solution and refinement.

The structures were solved by dual-space algorithm and refined in anisotropic approximation for non-hydrogen atoms against $F^2(hkl)$. Hydrogen atoms of methyl, methylene and aromatic fragments were calculated according to those idealized geometry and refined with constraints applied to C–H lengths and equivalent displacement parameters. All structures were solved with the ShelXT⁶ program and refined with the ShelXL⁷ program. Molecular graphics was drawn using OLEX2⁸ program.

Table S3. Crystallographic data for **6e**, **7d**, **8e** and **9e**



Compound	6e	7d	8e	9e
Formula moiety	C ₁₄ H ₁₅ NO ₃ S ₂	C ₁₉ H ₁₇ N ₃ O ₃ S ₂	C ₁₄ H ₁₅ NO ₂ S ₃	C ₁₅ H ₁₈ N ₂ O ₂ S
Brutto formula	C ₁₄ H ₁₅ NO ₃ S ₂	C ₁₉ H ₁₇ N ₃ O ₃ S ₂	C ₁₄ H ₁₅ NO ₂ S ₃	C ₁₅ H ₁₈ N ₂ O ₂ S
Formula weight	309.39	399.47	325.45	290.37
Diffractometer	Bruker APEX-II CCD	Bruker APEX-II CCD	Bruker APEX-II CCD	Bruker APEX-II CCD
Scan mode	ϕ and ω scans	ϕ and ω scans	ϕ and ω scans	ω and ϕ scans
Anode [Wavelength, Å]	MoK α [0.71073] ?	MoK α [0.71073] sealed tube	MoK α [0.71073] ?	MoK α [0.71073] sealed tube
Crystal Dimensions, mm	0.06 \times 0.17 \times 0.2	0.34 \times 0.34 \times 0.34	0.08 \times 0.1 \times 0.15	0.24 \times 0.31 \times 0.36
Crystal color	clear colourless	colourless	clear light yellow	colourless
Crystal system	monoclinic	orthorhombic	monoclinic	orthorhombic
a, Å	26.025(4)	9.3620(13)	8.9341(6)	7.7800(7)
b, Å	8.2676(12)	15.150(2)	9.2396(7)	18.5843(16)
c, Å	14.964(2)	26.466(4)	18.5187(14)	20.5791(18)
α , °	90	90	90	90
β , °	120.303(4)	90	99.163(2)	90
γ , °	90	90	90	90
Volume, Å ³	2779.8(7)	3754.0(9)	1509.17(19)	2975.4(5)
Density, gcm ⁻³	1.479	1.414	1.432	1.296
Temperature, K	120	120	120	120
T _{min} /T _{max}	0.5323/0.7461	0.6278/0.7461	0.6851/0.7461	0.6923/0.7461
μ , mm ⁻¹	0.389	0.309	0.491	0.220



Space group	C12/c1	Pbca	P12 ₁ /n1	Pbca
Z	8	8	4	8
F(000)	1296	1664	680	1232
Reflections collected	17844	34413	12815	48812
Independent reflections	4271	5741	4470	4570
Reflections (I>2σ(I))	2799	3762	3822	3306
Parameters	184	246	183	184
R _{int}	0.0841	0.0716	0.0193	0.0429
2θ _{min} - 2θ _{max} , °	3.626 - 61.344	5.330 - 61.108	4.456 - 61.060	3.958 - 61.260
wR ₂ (all reflections)	0.1522	0.1104	0.0754	0.0989
R ₁ (I>σ(I))	0.0554	0.0477	0.0288	0.0364
GOF	1.018	1.026	1.061	1.092
ρ _{min} /ρ _{max} , eÅ ⁻³	-0.523/0.509	-0.324/0.347	-0.298/0.371	-0.306/0.312



6. References



1. I. V. Tiushina, A. I. Sokolov, A. Yu. Smirnov, M. A. Dubinnyi, D. S. Ivanov, A. A. Korlyukov, A. A. Mikhaylov, M. S. Baranov, *ChemistrySelect* **2024**, 9, e202400930.
2. S. O. Zaitseva, S. V. Golodukhina, N. S. Baleeva, E. A. Levina, A. Yu. Smirnov, M. B. Zagudaylova, M. S. Baranov, *ChemistrySelect* **2018**, 3, 8593–8596.
3. Y. G. Ermakova, T. Sen, Y. A. Bogdanova, A. Yu. Smirnov, N. S. Baleeva, A. I. Krylov, M. S. Baranov, *J. Phys. Chem. Lett.* **2018**, 9, 1958–1963.
4. A. Thaqi, J. L. Scott, J. Gilbert, J. A. Sakoff, A. McCluskey, *European Journal of Medicinal Chemistry* **2010**, 45, 1717–1723.
5. Bruker (2016). APEX3, RLATT, CELL_NOW, TWINABS, SAINT-Plus and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
6. G. M. Sheldrick, *Acta Crystallogr A Found Adv* **2015**, 71, 3–8.
7. G. M. Sheldrick, *Acta Crystallogr C Struct Chem* **2015**, 71, 3–8.
8. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *J Appl Crystallogr* **2009**, 42, 339–341.



7. Copies of NMR spectra




























ME HSQC NMR spectrum of **6b**























































8. Copies of mass-spectra

